Colorectal cancer organoid culture medium and scaffold-free 3D culture method
By using scaffold-free culture medium and 3D cell sphere culture method with specific components, the problem of localization of exogenous matrix materials is solved, and the stable growth and size uniformity of colorectal cancer organoids is achieved, providing a more reliable evaluation of drug sensitivity , support the formulation of individualized treatment plans.
Patent Information
- Application Number
- CN202111479294.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-06
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2041-12-06
AI Technical Summary
There are limitations of exogenous matrix materials in the existing colorectal cancer organoid culture system, resulting in poor cell growth, limited nutrient exchange, uneven model size and uncertainty in drug test results.
None of the ingredients used in penicillin, streptomycin, ROCK1 inhibitor, MAPK inhibitor, ALK-5 inhibitor, R-Spondin-1, HEPES, GlutaMAX, B-27, N-2, EGF, Noggin and gastrin Scaffold culture medium combined with scaffold-free 3D cell spherical culture method to achieve stable growth and size uniformity of organoids.
It has achieved rapid formation of colorectal cancer organoids, tightly aggregation of cell spheres, smooth and round surface, clear boundaries, and long-term stable cultivation, providing more reliable drug sensitivity evaluation data, and providing experimental reference for individualized treatment plans.
Smart Images

Figure CN114181903B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a colorectal cancer organoid culture medium and a scaffold-free 3D culture method. Background Art
[0002] At present, the treatment of colorectal cancer mainly relies on surgery, radiotherapy and chemotherapy. Although adjuvant treatments such as biological agents and immunotherapy are emerging, their efficacy is still relatively limited. In the past, colorectal cancer research mainly relied on cell models and animal models, but these models have certain limitations. The organoid models that have emerged in recent years allow us to simulate various aspects of tumor characteristics in vivo more efficiently and realistically in vitro, providing a more reliable tool and bridge for basic research and its transformation into clinical applications.
[0003] Compared with tumors driven by a single factor, the prominent feature of colorectal cancer is the genetic and phenotypic heterogeneity between patients, and its pathogenesis is diverse. As a new experimental model, tumor organoids play an important role in colorectal cancer mechanism research, genomic research, anti-tumor drug screening, and tumor animal model establishment. In 2007, Barker N et al. from the Clevers Laboratory in the Netherlands found that cells carrying the LGR5 receptor produce all cells in the mouse intestine, and molecules in the Wnt signaling pathway guide these cells to divide. In 2009, Sato T et al. from the Netherlands used Lgr5 at the bottom of the mouse intestinal epithelial crypts to +Columnar cells were cultured in matrix gel to form organoids; in 2011, Jung et al. used the same method to culture cells with high expression of EphB2 in human colorectal mucosa into colorectal organoids. In the same year, Sato T et al. successfully cultured colorectal tumor organoids derived from patient tumor tissue. The in vitro construction of patient-derived colorectal cancer tumor organoids can simulate the in vivo 3D growth environment in vitro. Compared with the traditional 2D culture system, the 3D culture system can more realistically reflect the intestinal function and the signal transduction and morphology in the body, and has a high degree of tissue consistency with the primary tumor. Therefore, tumor organoids have become a hot topic among scientists and are used to study the pathological mechanisms of the occurrence and development of colorectal cancer and the in vitro screening of anti-tumor drugs. However, the current conventional colorectal cancer tumor organoid culture system basically continues the method established by Sato T et al., using exogenous matrix materials such as matrix glue and hydrogel for 3D cell culture. However, this culture system has certain limitations. The presence of exogenous matrix limits the gas exchange and material metabolism between organoids and the outside world. When the organoids form larger tissues, the lack of a circulatory system and the limitations of oxygen and nutrient exchange seriously affect the absorption of nutrients required by the organoids and the removal of metabolic waste. In addition, due to the presence of exogenous matrix around the 3D cell spheres, in situ optical detection cannot be performed, and the process of removing the exogenous matrix is not only cumbersome, but also affects cell activity to a certain extent, interfering with the authenticity of the experimental results.
[0004] A Chinese patent application (application number 202110109040.X) discloses a culture medium for culturing colorectal cancer organoids and a preparation method thereof. The culture medium involved in this technical invention contains a variety of cytokines, signal pathway regulatory factors, amino acids and serum-free additives, etc., and is composed of 17 raw materials; the organoids constructed based on the culture medium use culture medium and matrix gel in a volume ratio of 3:4 to inoculate cells, each gel drop is 40-60μL, and then placed at 37°C, 5% CO2 conditions for culture to obtain colorectal cancer organoids.
[0005] The Chinese patent application (application number 202011052642.8) discloses a method for culturing human colorectal cancer tumor organoids and its application. The organoid culturing method disclosed in the technical invention involves a culture medium containing more than ten kinds of raw materials such as cytokines, signaling pathway regulatory factors, antibiotics and serum-free additives. The organoid construction method involved in the patented technology is to mix the obtained cell mass with the hydrogel, add the human colorectal cancer organoid culture medium after solidification, and culture it to obtain human colorectal cancer organoids.
[0006] A Chinese patent application (application number 202011211090.0) discloses a method and culture medium for culturing colorectal cancer organoids. The culture medium involved in the technical invention uses a cell line that produces Wnt-3a, R-Spondin1 and Noggin to replace three expensive cytokines, saving the culture components of the organoids. However, the organoid construction method involved in the patented technology still requires the introduction of matrix gel, and the cell suspension and matrix gel are mixed in a volume ratio of 1:1.5-3. The resulting mixture is inoculated and cultured to obtain organoids.
[0007] The organoid construction and culture methods involved in the above three patents still use the conventional culture system based on the introduction of exogenous matrix such as matrix gel or hydrogel.
[0008] The above-mentioned organoid culture requires the introduction of exogenous scaffold materials, which leads to defects such as poor cell growth and difficulty in removing the scaffold materials. In addition, the obtained organoid models are uneven in size and may have problems with the response of different drugs. Summary of the invention
[0009] The purpose of the invention is to provide a colorectal cancer organoid culture medium.
[0010] The culture medium involved has a simple composition, a reasonable formula, and rich nutrition, which can meet the stable growth of colon cancer organoid cell spheres; the scaffold-free organoid construction method established by the present invention can quickly form organoids with uniform size, tightly aggregated cell spheres, smooth and rounded surfaces, clear boundaries, and stable genetic and biological traits. The in vitro tumor organoid model of colorectal cancer patients established by the present invention can be used for in vitro drug sensitivity evaluation, providing effective experimental data reference for the formulation of individualized treatment plans for patients.
[0011] The above technical objectives of the present invention are achieved through the following technical solutions:
[0012] A colorectal cancer organoid culture medium, the culture medium components comprising: penicillin, streptomycin, ROCK1 inhibitor, MAPK inhibitor, ALK-5 inhibitor, R-Spondin-1, HEPES, GlutaMAX, B-27, N-2, EGF, Noggin, gastrin (GastrinⅠ) and Advanced DMEM / F12 basic culture medium.
[0013] Preferably, the basal culture medium in the above-mentioned colorectal cancer organoid culture medium is Advanced DMEM / F12 culture medium.
[0014] Preferably, the ROCK1 inhibitor in the above-mentioned colorectal cancer organoid culture medium is Y-27632.
[0015] Preferably, the MAPK inhibitor in the above-mentioned colorectal cancer organoid culture medium is SB202190.
[0016] Preferably, the ALK-5 inhibitor in the above-mentioned colorectal cancer organoid culture medium is A83-01.
[0017] Furthermore, the above-mentioned colorectal cancer organoid culture medium, specifically a culture medium for colorectal cancer scaffold-free organoid 3D cell sphere culture, is composed of the following components in concentration or volume percentage:
[0018] Table 1 Composition of culture medium for colorectal cancer scaffold-free organoids
[0019] raw material Final concentration Specification brand Double antibiotics (penicillin / streptomycin) 0.5-2% 100mL Gibco Y-27632 5-20μM 25mg Blue Sky A83-01 0.5-1μM 25mg Blue Sky SB202190 5-20μM 25mg Blue Sky R-Spondin-1 0.2-1 μg / mL 500 μg Novoprotein HEPES 1-3% 20mL Gibco GlutaMAX(Glutamine) 0.5-3% 100mL Gibco B-27(50×) 1-3% 10mL Gibco N-2(100×) 0.5-2% 5mL Gibco EGF (Epidermal Growth Factor) 0.01-0.1 μg / mL 500 μg Novoprotein Noggin 0.05-0.5 μg / mL 500 μg Novoprotein Gastrin I 5-50nM 500 μg Novoprotein Advanced DMEM / F12 Refill to required volume 500mL Gibco
[0020] The main functions of the colorectal cancer organoid culture medium components invented in this patent are as follows: dual antibiotics (penicillin / streptomycin) inhibit bacterial growth and reduce the possibility of bacterial infection during tumor cell culture; Y-27632 is a ROCK inhibitor that has the effect of preventing cell apoptosis; A83-01 is a TGF-β1 receptor inhibitor, which is added to the culture medium to maintain cell stemness and inhibit cell differentiation; SB202190 is an effective p38 MAPK inhibitor; R-Spondin-1 participates in regulating cell proliferation and differentiation by activating and coordinating the Wnt / β-catenin signaling pathway; HEPES is a buffer used to maintain a stable pH value of the culture medium; GlutaMAX is an advanced cell culture additive that can directly replace L-glutamine in the cell culture medium, which can prevent the degradation of glutamine and minimize the accumulation of toxic ammonia components during long-term culture, and improve cell activity; B-27 and N-2 are cell-free serum culture additives to maintain cell activity; Noggin is an important embryonic protein that plays an important role in the formation of embryonic dorsal-ventral axis pattern, neural tube development and neural induction; EGF is an important cell growth factor secreted by the human body, which has strong physiological activity, such as promoting the proliferation of epithelial cells and fibroblasts; GastrinⅠ has a proliferative effect on primary cultured colorectal cancer cells. Advanced DMEM / F12 is a basic culture medium for cell culture.
[0021] The above-mentioned culture medium composition is the optimal composition for scaffold-free organoid culture of colorectal cancer obtained in the experiment. After reducing one or several components, the success rate of culturing primary colorectal cancer tumor cells into 3D cell spheres decreases, and it may even be difficult to form spheres. In addition, the growth rate of organoid cell spheres slows down, and even cell necrosis and sphere disintegration occur, making it difficult to achieve long-term stable culture.
[0022] The culture medium of the present invention is suitable for the culture of colorectal cancer organoid cell spheres, especially the culture of scaffold-free organoids, and is also suitable for organoids constructed based on exogenous matrices.
[0023] The colorectal cancer organoid culture medium obtained by the method is a serum-free culture medium.
[0024] Another object of the invention is to provide a scaffold-free 3D culture method for colorectal cancer organoids.
[0025] The above technical objectives of the present invention are achieved through the following technical solutions:
[0026] A scaffold-free 3D culture method for colorectal cancer organoid culture medium, comprising at least the following steps:
[0027] S01, directly inoculating the digested and separated primary tumor cells into ultra-low adsorption cell culture well plates;
[0028] S02, adding the above-mentioned colorectal cancer organoid culture medium;
[0029] S03. Replace the culture medium every 2 to 3 days and culture until organoids are formed.
[0030] Optionally or preferably, in step S01, the method for separating and digesting primary tumor cells is to take the tumor tissue, rinse it, cut it into pieces, add it into a single cell suspension preparation instrument to enzymatically hydrolyze the tumor tissue, and separate and obtain primary cells;
[0031] The water bath temperature of the single-cell suspension preparation instrument was set to 38.5°C, the instrument speed was 150 rpm, and it ran clockwise and counterclockwise for 5 min respectively;
[0032] Optionally or preferably, the digestion solution of the single cell suspension preparation instrument is composed of the following components by volume: 0.1-0.5% type I collagenase, 0.1-0.5% type IV collagenase, and the balance is Hank's solution (without Ca 2+ Mg 2+ ).
[0033] Collagenase is used to degrade extracellular matrix components and separate cells when primary cell culture is carried out. Different tissue types require different collagenases. The combination selected by the present invention is set by the inventor based on the properties of primary cell tumors. It has a fast digestion speed and can complete the digestion of colorectal cancer tumor tissue in 20 minutes, greatly reducing the damage caused to primary tumor cells during the digestion of tumor tissue.
[0034] Optionally or preferably, in step S01, the primary tumor cells are derived from tumor tissue obtained by surgical resection or biopsy from a tumor patient who has not received any anti-tumor treatment;
[0035] The method for obtaining tumor tissue obtained by surgical resection or biopsy of a tumor patient comprises at least the following steps:
[0036] S10. Place fresh tumor tissue in 4°C precooled tissue washing solution, remove blood clots, necrotic tissue, fat and connective tissue on the tissue specimen, and retain the active tumor tissue;
[0037] S11. Wash with tissue washing solution until the supernatant is clear, and cut the tissue into 1 mm pieces with sterile ophthalmic scissors in a centrifuge tube. 3 Small pieces of about 100 μg / cm2 were added with tissue preservation solution and transferred to the laboratory at 0-4°C for subsequent separation and extraction of primary tumor cells.
[0038] Optionally or preferably, the tissue washing solution is: a PBS solution containing 500 U / mL penicillin / streptomycin, or one or both of 5-20 μg / mL amphotericin B and 1-5 μg / mL metronidazole.
[0039] Optionally or preferably, the present invention preferably contains a PBS solution of 500 U / mL penicillin, 500 μg / mL streptomycin and 12.5 mg / L amphotericin B.
[0040] Optionally or preferably, after the isolated and obtained primary colorectal cancer tumor cells are counted, the primary cells are inoculated into an ultra-low adsorption well plate at a density of 1000-10000 cells / well, supplemented with 100-150 μL of organoid culture medium, and centrifuged at 1000 rpm for 3 min to promote cell aggregation and faster assembly to form organoid cell spheres, and the culture medium is replaced every 2-3 days.
[0041] Optionally or preferably, the cell seeding density is 2000-6000 cells / well.
[0042] If the initial cell amount is too small, it will be difficult for cells to aggregate and form spheres, while if the initial cell amount is too large, it will affect the spheroidization and growth of cell spheres. When the cell density exceeds 10,000 cells / well, necrosis in the center of the cell spheres is likely to occur, resulting in the failure of organoid spheroidization.
[0043] Optionally or preferably, when the diameter of the organoid cell sphere obtained by culture by the method is greater than 300 μm, the organoid cell sphere needs to be subjected to step S04: digestion and passaging;
[0044] The specific method is:
[0045] S41: Collect the culture medium in the well and the organoids into a centrifuge tube, centrifuge at 300g for 3 minutes to collect the cell pellet, add 1-2mL of enzymatic solution, incubate at 37℃ for 10-15 minutes, and gently blow to disperse the organoid cell spheres;
[0046] S42: After enzymatic hydrolysis, add an appropriate amount of organoid culture medium and gently pipette to mix, centrifuge at 300g for 3 minutes to collect the precipitate, and passage at a ratio of 1:3.
[0047] Optionally or preferably, the enzymatic hydrolysis solution is TrypLE.
[0048] The colorectal cancer organoid culture medium provided by the present invention is also applicable to a tumor organoid culture method with a matrix, that is, the culture medium of the present invention is also applicable to an organoid culture method with a scaffold.
[0049] Another object of the present invention is to provide another method for culturing colorectal cancer organoid culture medium, comprising at least the following steps:
[0050] S01, counting the isolated primary colorectal cancer tumor cells, and collecting the cell precipitates by centrifugation;
[0051] S02, resuspend the cells with matrix gel, adjust the cell density to 5000-10000 cells / 10 μL, inoculate into the cell culture plate at a volume of 10 μL per well, turn the cell plate upside down, and solidify for 30 minutes;
[0052] S03, adding the above-mentioned colorectal cancer organoid culture medium, and culturing at 37°C and 5% CO2;
[0053] S04. Replace the culture medium every 2 to 3 days until organoids are formed.
[0054] Optionally or preferably, the matrix gel is low growth factor Matrigel. Compared with the prior art, the present invention has the following beneficial effects:
[0055] 1. The present invention uses a PBS solution containing a high concentration of antibiotics to rinse the collected colorectal cancer tumor tissue, and uses a preservation solution to transport the tumor tissue, thereby reducing the possibility of bacterial contamination in subsequent cell culture, maintaining cell activity to the greatest extent, and improving the subsequent tumor tissue primary cell isolation activity and the success rate of organoid construction and culture.
[0056] 2. The present invention provides a scaffold-free organoid culture medium and culture method for colorectal cancer, which can realize the autonomous aggregation of cells to form tumor organoid cell spheres without carrier support, and the generation is rapid, spheres can be formed within 24 hours, and they can self-assemble into tumor organoid 3D cell spheres within 72 hours, and can be cultured stably for a long time.
[0057] 3. Compared with traditional 2D culture, organoid 3D cell spheres can well preserve the heterogeneity of patient tumor tissues in vitro, and can more realistically reflect the sensitivity of colorectal cancer to therapeutic drugs in patients. The drug sensitivity screening data based on this model has a higher reference value for the formulation of personalized treatment plans for the source patients.
[0058] 4. The size of organoid cell spheres may affect the response time and effect of cells to drugs, thereby affecting the judgment of drug sensitivity test results. The scaffold-free 3D organoid culture method for colorectal cancer provided by the present invention can accurately control the generation of cultured organoid spheres. The formed tumor organoid cell spheres have regular spherical shapes and uniform and controllable sizes, which effectively avoids the impact of uneven organoid cell sphere sizes on drug sensitivity tests. It is an ideal model for in vitro drug sensitivity screening and can be used as a test platform for in vitro individualized sensitivity detection of therapeutic drugs for colorectal cancer patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] Figure 1 Schematic diagram of colorectal cancer tumor organoids (10×) constructed based on the scaffold-free method;
[0060] Figure 2 This is a schematic diagram of colorectal cancer tumor organoids constructed based on Matrigel (20×);
[0061] Figure 3 is the spheroidization rate of scaffold-free tumor organoids constructed under different culture medium conditions at 3 days;
[0062] Figure 4 Schematic diagram of the colon cancer organoid model before and after drug administration. DETAILED DESCRIPTION
[0063] The present invention is further described in detail below in conjunction with the accompanying drawings.
[0064] Example 1: Preparation of colorectal cancer organoid culture medium
[0065] Y-27632 10 μM, A 83-01 500 nM, SB202190 10 μM, FBS 20%, double antibody (penicillin / streptomycin) 1%, Advanced DMEM / F12 supplemented to the required volume.
[0066] Example 2: Pretreatment of fresh tumor tissue
[0067] Tissue washing solution: PBS solution containing 500U / mL penicillin / streptomycin and 12.5mg / L amphotericin B, filtered and sterilized.
[0068] Tissue preservation medium: tissue preservation and transport medium (serum-free chemical medium, Life Science Production Company)
[0069] Fresh colorectal cancer tumor tissue processing process:
[0070] (1) Place fresh tumor tissue obtained from colorectal cancer patients by surgery or colonoscopy in a 4°C precooled tissue washing solution, and remove blood clots, necrotic tissue, fat, and connective tissue from the tissue specimen.
[0071] (2) Use tissue washing solution to clean the tumor tissue. Due to the location where the tumor tissue is collected, it is easy to be contaminated and needs to be cleaned at least 3-5 times.
[0072] (3) After the tumor tissue is cleaned, it is cut into small pieces with sterile ophthalmic scissors in a centrifuge tube. The size of the tissue piece is 1 mm 3 about.
[0073] (4) If the tissue acquisition site has the conditions for subsequent tumor cell isolation and extraction, add tissue preservation fluid to the above-mentioned shredded tissue blocks and quickly transfer them to the laboratory for subsequent tumor cell isolation and extraction to prevent autolysis or apoptosis of cells in the tissue. If the tissue acquisition site does not have the conditions for subsequent processing, please proceed to step (5).
[0074] (5) Add at least 6 times the volume of tissue preservation solution to the chopped tissue blocks, place them in a 4°C refrigerator for temporary storage, and use a biological refrigerator for express delivery. The samples must be transported to the laboratory for subsequent processing within 72 hours.
[0075] Example 3: Isolation of primary colorectal cancer tumor cells
[0076] Tissue digestion solution: Hank's solution (Ca-free) containing 0.1% (mass percentage) type I collagen and 0.1% (mass percentage) type IV collagen. 2+ Mg 2+ ).
[0077] Isolation steps of primary colorectal cancer tumor cells:
[0078] (1) Sample washing: Wash the tissue sample 2-3 times with washing solution until the solution is clear, and centrifuge at 200g for 3 minutes to collect the sample precipitate;
[0079] (2) Tissue digestion: Add 3 mL of digestion solution to resuspend the sample and transfer it to a sterile centrifuge tube provided with the single-cell suspension preparation instrument. Then, invert the centrifuge tube and install it on the single-cell suspension preparation instrument. Set the water bath temperature to 38.5°C and the instrument speed to 150 rpm. Run the instrument clockwise and counterclockwise for 5 min each and then stop.
[0080] (3) Cell separation: remove the centrifuge tube containing the sample, pass the digestion solution through a 70 μm cell mesh sieve, and rinse the centrifuge tube wall and tube cap with basal culture medium to collect the cells as completely as possible; the remaining sample in the tube and the sample not filtered on the mesh sieve need to be collected and digested a second time, according to operation step (2);
[0081] (4) Cell counting: Combine the cell filtrates collected from the two digestions, centrifuge at 1000 rpm for 5 min, discard the supernatant, collect the cell pellet, add 1 mL of organoid culture medium to resuspend the cells; take 10 μL of the cell suspension, add 10 μL of trypan blue dye, mix well, count and determine the cell viability using a cell counter, and calculate the proportion of live cells.
[0082] Example 4: Construction of colorectal cancer tumor organoids
[0083] The culture medium provided by the technology of the present invention is particularly suitable for the construction of colorectal cancer scaffold-free organoids, and is also suitable for the construction of colorectal cancer scaffolded tumor organoids.
[0084] (1) Construction of scaffold-free colorectal cancer tumor organoids
[0085] After counting the isolated primary colorectal cancer cells, the primary cells were inoculated into a 96-well plate for organoids (U-shaped or V-shaped plate for ultra-low adsorption cell culture) at a density of 2500 cells / well, supplemented with 100 μL of organoid culture medium, centrifuged at 1000 rpm for 3 minutes to promote cell aggregation, and cultured at 37°C and 5% CO2. The culture medium was replaced every 2-3 days, and 1 / 2 of the culture medium could be replaced according to the cell proliferation. After 3 days of culture, the primary cells were observed to self-assemble into 3D cell spheres of tumor organoids, such as Figure 1 As shown in the figure, within a certain period of time, the volume of the cell sphere increases with the increase of culture time. Compared with the organoid construction method with the introduction of matrix gel scaffold, the organoid cell spheres established by the scaffold-free organoid construction method are uniform in size, tightly aggregated, and have a relatively smooth and rounded surface.
[0086] (2) Construction of colorectal cancer scaffolded tumor organoids
[0087] After counting the isolated primary colorectal cancer cells, the cell precipitates were collected by centrifugation and resuspended with low growth factor Matrigel (matrigel). The cell density was adjusted to 5000-10000 cells / 10μL, and the cells were inoculated into 24-well plates at a volume of 10μL per well. The well plates were inverted and placed in an incubator for 30 minutes to allow the colloid to solidify, and then 1mL of complete culture medium was added to each well; the plates were cultured at 37°C and 5% CO2, and the culture medium was replaced every 2-3 days. 1 / 2 of the culture medium can be replaced according to the cell proliferation. After 5 days of culture, tumor organoid 3D cell spheres can be observed, such as Figure 2 shown.
[0088] Example 5: Passaging of Tumor Organoids
[0089] When the diameter of unscaffolded organoids exceeds 300 μm or the density of scaffolded organoids in matrix gel is too high, they need to be passaged to maintain the good condition and faster proliferation rate of the organoids.
[0090] For organoids with scaffolds, transfer the culture medium in the well plate together with Matrigel to a 15mL centrifuge tube, add 8mL PBS, gently blow and mix until the colloid is dispersed and no large colloid is present, and centrifuge at 300g for 3min to collect the cell pellet. For organoids without scaffolds, directly collect the culture medium in the well together with the organoids into a centrifuge tube, and centrifuge at 300g for 3min to collect the cell pellet. Compared with the collection process of organoids with scaffolds, organoids without scaffolds do not need to remove the colloid, thus avoiding the damage to the organoid cell spheres caused by the blowing and removing colloid process and maintaining the cell characteristics.
[0091] For the collected organoid precipitate, add 1-2 mL of enzymatic hydrolysis solution (TrypLE) and gently blow to disperse the organoid cell spheres. Incubate at 37°C while observing under the microscope until the organoids are dispersed into small cell clusters of 3-5 cells. The enzymatic hydrolysis process takes about 10-15 minutes. After the enzymatic hydrolysis is completed, add 5 mL of organoid culture medium and gently blow to mix. Centrifuge at 300g for 3 minutes to collect the precipitate and passage it at a ratio of 1:2-1:3.
[0092] Example 6: Cryopreservation of Tumor Organoids
[0093] According to the method of tumor organoid passaging in Example 5, the cell sphere precipitation of organoids without scaffold and with scaffold was collected, and then resuspended with freezing solution (90% FBS + 10% DMSO), and divided into cryotubes. The cryotubes were then transferred to a programmed cooling cryobox, placed in a -80°C refrigerator overnight, and then transferred to a liquid nitrogen tank for long-term storage.
[0094] Example 7: The role of cytokines in the construction of organoid 3D cell spheres. Seven experimental groups were set up: ① organoid complete medium group, ② Y-27632-deficient medium group, ③ A83-01-deficient medium group, ④ SB202190-deficient medium group, ⑤ R-Spondin-1-deficient medium group, ⑥ Noggin-deficient medium group and ⑦ GastrinⅠ-deficient medium group. The component-deficient medium group only lacked one component, and the remaining components were completely consistent with the components of the organoid complete medium. Tumor primary cells were isolated and obtained according to Example 3, and the construction method of scaffold-free organoids in Example 4 was used to construct and culture organoids. Each experimental group was set up with 9 replicates.
[0095] The organoid cell spheres cultured in the complete culture medium of the present invention were round and complete, with clear boundaries and good light transmittance; the sphere formation rates of the organoids in the component-deficient group were reduced to varying degrees, and as the culture time increased, the organoid spheres grew slowly, stagnated, and even collapsed and apoptotic. The sphere formation rates of the scaffold-free tumor organoids in each experimental group at 3 days after construction were as follows: Figure 3 shown.
[0096] Example 8: In vitro drug sensitivity screening based on 2D culture of primary tumor cells and 3D organoid model The technology of the present invention was used to culture tumor cells from colon cancer patients in 2D and 3D culture of scaffold-free organoid model, and in vitro drug sensitivity detection of chemotherapy drugs was performed based on 2D cultured cells and 3D tumor organoid model, and the differences in drug sensitivity of different models were compared. A total of 7 dosing regimens, including 4 single drugs and 3 combined administrations, were selected for testing. The peak plasma concentration (PPC) of 5-fluorouracil was 4.0 μM (2.08 μg / mL); the PPC of oxaliplatin was 1.0 μg / mL; the PPC of capecitabine was 5.0 μg / mL; the PPC of irinotecan was 7.7 μg / mL; capecitabine + oxaliplatin, the two were co-administered in a 1:1 ratio; capecitabine + irinotecan: the two were co-administered in a 1:1 ratio; 5-fluorouracil + oxaliplatin: the two were co-administered in a 1:1 ratio.
[0097] Unscaffolded tumor organoid cell spheres were inoculated at a density of 2500 cells / well and were administered after 3 days of culture. Tumor 2D cultured primary cells were inoculated in 96-well cell culture plates at the same cell density and administered after 3 days of culture. The drug concentrations were set at 12.5%, 25%, 50%, 100% and 200% PPC. A normal control group was set up and normal culture was performed without drug administration. Each concentration was repeated 6 times. The ATP bioluminescence method was used to detect the changes in ATP activity of 2D cultured cells and organoid 3D cell spheres on the 3rd, 5th and 7th days after drug administration. The sensitivity of the drug was determined according to the in vitro drug sensitivity evaluation criteria. The results are shown in Table 2. Sensitivity evaluation criteria: Strongly sensitive (SS): IC50 < 25% and IC90 < 100% PPC; Moderately sensitive (IS): IC50 < 25% and IC90 > 100% PPC; Mildly sensitive (MS): IC50 > 25% and IC90 < 100% PPC; Resistant (R): IC50 > 25% and IC90 > 100% PPC; IC90 indicates the percentage of the peak plasma concentration that inhibits the growth of 90% of tumor cells; IC50 indicates the percentage of the peak plasma concentration that inhibits the growth of half of the tumor cells; PPC indicates the peak plasma concentration corresponding to a certain clinical drug dose. The organoid 3D cell spheres in the sensitive dosing regimen group showed certain disintegration and apoptosis after administration, such as Figure 4 shown.
[0098] Table 2: Results of drug sensitivity test of in vitro colon cancer tumor cell model
[0099]
[0100] As can be seen from Table 2, both 2D cultured primary tumor cells and organoid 3D cell sphere models derived from tumor tissues of patients with colon cancer were resistant to capecitabine and capecitabine + oxaliplatin; the two tumor cell models showed different sensitivities to the three dosing regimens of 5-fluorouracil, oxaliplatin and 5-fluorouracil + oxaliplatin. The 2D cultured tumor cells showed different degrees of sensitivity, while the organoid 3D cell spheres showed resistance, indicating that compared with 2D cultured cells, the tolerance of primary tumor cells to drugs was enhanced after self-assembly into 3D cell spheres; both models showed strong sensitivity to irinotecan and capecitabine + irinotecan dosing regimens at 7 days of dosing, indicating that these two dosing regimens may be sensitive to the tumor patients. An overall comparison of the drug sensitivity results of the two in vitro tumor cell models shows that compared with 2D cultured primary tumor cells, due to their self-assembly into organoid structures, which are closer to the in vivo tumor tissue structure, the organoid 3D cell spheres have higher tolerance to drugs, and their results are more reasonable and have clinical reference value.
[0101] The invention concept is described in detail using specific examples herein, and the description of the above embodiments is only used to help understand the core idea of the invention. It should be pointed out that any obvious modification, equivalent substitution or other improvement made by a person of ordinary skill in the art without departing from the invention concept should be included in the protection scope of the present invention.
Claims
1. A scaffold-free 3D culture method for colorectal cancer organoid culture medium, characterized in that: The method comprises at least the following steps: S01, directly inoculating the digested and separated primary tumor cells into ultra-low adsorption cell culture well plates; S02, adding colorectal cancer organoid culture medium; S03. Replace the culture medium every 2 to 3 days and culture until organoids are formed; Among them, the components of colorectal cancer organoid culture medium are: 0.5-2% penicillin, 0.5-2% streptomycin, 5-20μM ROCK1 inhibitor, 5-20μM MAPK inhibitor, 0.5-1μM ALK-5 inhibitor, 0.2-1 μg / mL R-Spondin -1, 1-3% HEPES, 0.5-3% GlutaMAX, 1-3% B-27, 0.5-2% N-2, 0.01-0.1μg / mL EGF, 0.05-0.5μg / mL Noggin, 5-50 nM gastrin Ⅰ, and the rest are Advanced DMEM / F12 basal culture medium.
2. The scaffold-free 3D culture method for colorectal cancer organoid culture medium according to claim 1, characterized in that: The ROCK1 inhibitor is Y-27632.
3. The scaffold-free 3D culture method for colorectal cancer organoid culture medium according to claim 1, characterized in that: The MAPK inhibitor is SB202190.
4. The scaffold-free 3D culture method for colorectal cancer organoid culture medium according to claim 1, characterized in that: The ALK-5 inhibitor is A83-01.
5. The scaffold-free 3D culture method for colorectal cancer organoid culture medium according to claim 1, characterized in that: In step S01, the method for separating and digesting primary tumor cells is to wash the tumor tissue, cut it into pieces, add a single cell suspension preparation instrument to enzymatically hydrolyze the tumor tissue, and separate and obtain primary cells; The water bath temperature of the single-cell suspension preparation instrument was set to 38.5°C, the instrument speed was 150 rpm, and it ran clockwise and counterclockwise for 5 minutes respectively.
6. The method for 3D culture of colorectal cancer organoid culture medium without scaffold according to claim 5, characterized in that: The digestion solution in the single cell suspension preparation instrument is composed of the following components by volume: 0.1-0.5% type I collagenase, 0.1-0.5% type IV collagenase, and the remainder is Ca-free. 2+ Mg 2+ Hank's solution.
7. The scaffold-free 3D culture method for colorectal cancer organoid culture medium according to claim 1, characterized in that: In step S01, the primary tumor cells are derived from tumor tissue obtained by surgical resection or biopsy from a tumor patient who has not received any anti-tumor treatment; The method for obtaining tumor tissue obtained by surgical resection or biopsy of a tumor patient comprises at least the following steps: S10. Place fresh tumor tissue in 4°C precooled tissue washing solution, remove blood clots, necrotic tissue, fat and connective tissue on the tissue specimen, and retain the active tumor tissue; S11. Wash with tissue washing solution until the supernatant is clear, and cut the tissue into 1 mm pieces with sterile ophthalmic scissors in a centrifuge tube. 3 Small pieces of about 100 μg / cm2 were added with tissue preservation solution and transferred to the laboratory at 0-4°C for subsequent separation and extraction of primary tumor cells.
8. The scaffold-free 3D culture method for colorectal cancer organoid culture medium according to claim 7, characterized in that: The tissue washing solution is a PBS solution containing 500 U / mL penicillin / streptomycin, or one or both of 5-20 μg / mL amphotericin B and 1-5 μg / mL metronidazole.
9. The scaffold-free 3D culture method for colorectal cancer organoid culture medium according to claim 8, characterized in that: The tissue washing solution is a PBS solution containing 500 U / mL penicillin, 500 μg / mL streptomycin and 12.5 mg / L amphotericin B.
10. The method for culturing colorectal cancer organoid culture medium without scaffold 3D according to claim 1, characterized in that: After counting, the isolated primary colorectal cancer tumor cells were inoculated into ultra-low adsorption well plates at a density of 1000-10000 cells / well, supplemented with 100-150 μL of organoid culture medium, and centrifuged at 1000 rpm for 3 minutes at room temperature to promote cell aggregation and assemble into organoid cell spheres more quickly.
11. The method for culturing colorectal cancer organoid culture medium without scaffold 3D according to claim 10, characterized in that: The cell seeding density is 2000-6000 cells / well.
12. The scaffold-free 3D culture method for colorectal cancer organoid culture medium according to claim 1, characterized in that: When the diameter of the organoid cell sphere obtained by the method is greater than 300 μm, the organoid cell sphere needs to be subjected to step S04: digestion and subculture. The steps of digestion and subculture are as follows: S41: Collect the culture medium in the well and the organoids into a centrifuge tube, centrifuge at 300g for 3 minutes to collect the cell pellet, add 1-2mL of enzymatic solution, incubate at 37℃ for 10-15 minutes, and gently blow to disperse the organoid cell spheres; S42: After enzymatic hydrolysis, add an appropriate amount of organoid culture medium and gently pipette to mix, centrifuge at 300g for 3 minutes to collect the precipitate, and passage at a ratio of 1:
3.
13. The scaffold-free 3D culture method for colorectal cancer organoid culture medium according to claim 12, characterized in that: The enzymatic hydrolysate is TrypLE.
Citation Information
Patent Citations
A method for culturing human colorectal cancer tissue organoids and its application
CN112195152B
Culture methods and culture media for colorectal cancer organoids
CN112266898B
A culture medium for colorectal cancer organoid culture and its preparation method
CN112813028B
In vitro culture method of colorectal cancer organoid
CN108396010A
Culture solution for colorectal cancer organoid culture and preparation method thereof
CN112813028A
